Oslo University Hospital HF

The Department of Cardiology at Oslo University Hospital HF drives forward innovative care for complex heart conditions. Current investigations assess heart transplantation outcomes and strategies to preserve renal function in transplant recipients.

• Heart transplantation outcomes
• Renal protection after cardiac allograft
• Tacrolimus minimization in low‑risk transplant recipients
• Long‑term safety of subcutaneous immune checkpoint inhibitors in cardiac patients

Across the site, 13 clinical trials involve 20 investigators, with several focused on cardiovascular health.

Research on digestive system diseases aims to improve therapeutic options for both rare and common gastrointestinal disorders. A priority study examines primary sclerosing cholangitis and its impact on liver function.

• Primary sclerosing cholangitis
• Resectable dMMR/MSI‑H colon cancer
• Advanced colorectal cancer therapies
• Liver involvement in mesothelioma

The portfolio includes trials on colon cancer staging and advanced cholangiopathy, contributing to the overall 13 studies conducted at the site.

The hematology program focuses on blood‑related disorders and immune deficiencies. A major effort evaluates haemophilia A treatment using extended‑half‑life factor concentrates.

• Haemophilia A management
• Acute lymphoblastic leukemia in infants
• Atypical teratoid/rhabdoid tumours (ATRT) in young children
• Kidney failure and transplantation outcomes

These efforts are part of the broader clinical research activity involving 20 investigators at Oslo University Hospital HF.

Oncologic trials at the centre target a wide range of solid tumours, seeking to extend survival and reduce disease burden. One prominent study investigates KRAS‑mutated non‑small cell lung cancer with a novel targeted agent.

• KRAS G12C‑mutated NSCLC
• Malignant pleural mesothelioma
• Metastatic melanoma immunotherapy
• HPV‑positive oropharyngeal carcinoma
• dMMR/MSI‑H colon cancer

The neoplasm portfolio contributes several of the 13 active trials, reflecting the institution’s commitment to cancer research.

Respiratory research centers on lung malignancies and mesothelioma, exploring new immunologic and targeted strategies. Current work assesses malignant pleural mesothelioma response to combination therapies.

• Malignant pleural mesothelioma
• KRAS‑mutated NSCLC
• Advanced lung cancer immunotherapy
• Bronchial involvement in HPV‑related cancers

These respiratory studies form a key component of the hospital’s 13‑trial clinical program.

The virology unit addresses emerging infectious threats and evaluates therapeutic options. A focused trial measures the efficacy of treatment for monkeypox infections.

• Monkeypox therapeutic trial
• Evaluation of antiviral agents
• Safety monitoring of viral vaccine candidates
• Diagnostic improvement for viral infections

Viral disease investigations complement the broader research agenda at Oslo University Hospital HF.

Some studies span multiple specialties or address rare conditions that do not fit conventional categories. An interdisciplinary project examines atypical teratoid/rhabdoid tumours in infants using novel consolidation regimens.

• Atypical teratoid/rhabdoid tumours in children
• Kidney transplantation immunosuppression minimization
• Peri‑operative dostarlimab in early‑stage colon cancer
• Physical activity monitoring in severe haemophilia A

These cross‑disciplinary efforts are included among the 13 trials conducted by 20 investigators at the Oslo University Hospital HF.